| Ident. | Authors (with country if any) | Title |
|---|
| 000361 |
S. Al-Sweidi [Canada] ; M. Morissette [Canada] ; T. Di Paolo [Canada] | Estrogen receptors modulate striatal metabotropic receptor type 5 in intact and MPTP male mice model of Parkinson's disease. |
| 001390 |
S. Al Sweidi [Canada] ; M. G. Sánchez [Canada] ; M. Bourque [Canada] ; M. Morissette [Canada] ; D. Dluzen [États-Unis] ; T. Di Paolo [Canada] | Oestrogen Receptors and Signalling Pathways: Implications for Neuroprotective Effects of Sex Steroids in Parkinson’s Disease |
| 001441 |
S. Al-Sweidi [Canada] ; M. Morissette [Canada] ; T. Di Paolo [Canada] | Effect of Oestrogen Receptors on Brain NMDA Receptors of 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine Mice |
| 001536 |
S. Al-Sweidi [Canada] ; M. Morissette [Canada] ; T. Di Paolo [Canada] | Effect of Oestrogen Receptors on Brain NMDA Receptors of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mice |
| 001D36 |
B. Ouattara [Canada] ; D. Hoyer [Suisse] ; L. Gregoire [Canada] ; M. Morissette [Canada] ; F. Gasparini [Suisse] ; B. Gomez-Mancilla [Suisse] ; T. Di Paolo [Canada] | CHANGES OF AMPA RECEPTORS IN MPTP MONKEYS WITH LEVODOPA-INDUCED DYSKINESIAS |
| 002A39 |
S. Jourdain [Canada] ; M. Morissette [Canada] ; N. Morin [Canada] ; T. Di Paolo [Canada] | Oestrogens Prevent Loss of Dopamine Transporter (DAT) and Vesicular Monoamine Transporter (VMAT2) in Substantia Nigra of 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine Mice |
| 002F18 |
A. Hadj Tahar [Canada] ; R. Grondin [Canada] ; L. Gregoire [Canada] ; F. Calon [Canada] ; T. Di Paolo [Canada] ; P. J. Bedard [Canada] | New insights in Parkinson's disease therapy: Can levodopa-induced dyskinesia ever be manageable |
| 003018 |
A. Ekue [Canada] ; J. Boulanger [Canada] ; M. Morissette [Canada] ; T. Di Paolo [Canada] | Lack of Effect of Testosterone and Dihydrotestosterone Compared to 17β‐Oestradiol in 1‐Methyl‐4‐Phenyl‐1,2,3,6, Tetrahydropyridine‐Mice |
| 003562 |
M. Goulet [Canada] ; R. Grondin [Canada] ; M. Morissette [Canada] ; S. Maltais [Canada] ; P. Falardeau [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada] | Regulation by chronic treatment with cabergoline of dopamine D1 and D2 receptor levels and their expression in the striatum of Parkinsonian-Monkeys |
| 003568 |
M. Grandbois [Canada] ; M. Morissette [Canada] ; S. Callier [Canada, France] ; T. Di Paolo [Canada] | Ovarian steroids and raloxifene prevent MPTP-induced dopamine depletion in mice |
| 003588 |
M. Cyr [Canada] ; F. Calon [Canada] ; M. Morissette [Canada] ; M. Grandbois [Canada] ; S. Callier [Canada, France] ; T. Di Paolo [Canada] | Drugs with estrogen-like potency and brain activity : Potential therapeutic application for the CNS |
| 003600 |
F. Calon [Canada] ; M. Morissette [Canada] ; M. Goulet [Canada] ; R. Grondin [Canada] ; P. J. Blanchet [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada] | 125I-CGP 64213 binding to GABAB receptors in the brain of monkeys : Effect of MPTP and dopaminomimetic treatments |
| 003829 |
R. Grondin [Canada] ; M. Goulet [Canada] ; M. Morissette [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada] | Dopamine D1 receptor mRNA and receptor levels in the striatum of MPTP monkeys chronically treated with SKF-82958 |
| 003B34 |
M. Goulet [Canada] ; M. Morissette [Canada] ; F. Calon [Canada] ; P. J Blanchet [Canada] ; P. Falardeau [Canada] ; P. J Bédard [Canada] ; T. Di Paolo [Canada] | Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: in situ hybridization histochemical analysis |
| 003E69 |
R. Grondin [Canada] ; M. Goulet [Canada] ; T. Di Paolo [Canada] ; P. J. Bédard [Canada] | Cabergoline, a long-acting dopamine D2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drug-naive primates |
| 003E98 |
M. Goulet [Canada] ; R. Grondin ; P. J. Blanchet ; P. J. Bedard ; T. Di Paolo [Canada] | Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode to not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys |
| 004027 |
F. Calon [Canada] ; M. Goulet [Canada] ; P. J. Blanchet [Canada] ; J. C. Martel [Canada] ; M. F. Piercey [États-Unis] ; P. J. Be Dard [Canada] ; T. Di Paolo [Canada] | Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA, receptors in the striatopallidal complex |
| 004030 |
Pj Blanchet [Canada] ; B. Gomez-Mancilla [Canada] ; T. Di Paolo [Canada] ; Pj Bédard [Canada] | Is striatal dopaminergic receptor imbalance responsible for levodopa‐induced dyskinesia? |
| 004453 |
B. Gomez-Mancilla [Canada] ; R. Boucher ; C. Gagnon ; T. Di Paolo ; R. Markstein ; P. J. Bedard | Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors |
| 004459 |
C. Gagnon [Canada] ; B. Gomez-Mancilla ; P. J. Bedard ; T. Di Paolo [Canada] | Chronic CY 208-243 treatment of MPTP-monkeys causes regional changes of dopamine and GABAA receptors |
| 004464 |
L. Rioux [Canada] ; C. Gagnon ; D. P. Gaudin [Canada] ; T. Di Paolo ; P. J. Bedard [Canada] | A fetal nigral graft prevents behavioral supersensitivity associated with repeated injections of L-dopa in 6-OHDA rats. Correlation with D1 and D2 receptors |
| 004897 |
C. Rouillard [Canada] ; P. J. Bédard [Canada] ; T. Di Paolo [Canada] | Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393 |
| 004B77 |
P. Falardeau [Canada] ; P. J. Bédard [Canada] ; T. Di Paolo [Canada] | Relation between brain dopamine loss and D2 dopamine receptor density in MPTP monkeys |
| 005637 |
C. Gagnon [Canada] ; P J Bédard ; T. Di Paolo | Grafts in the treatment of Parkinson's disease: animal models. |
